Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications

Introduction to the session

This summary report aims to capture the content of the session at EuroPCR 2018 that reviewed the implications for clinical practice of the SPYRAL HTN-OFF MED trial, in order to share a critical analysis of the trial and report the views expressed in the interactive discussion. This article does not constitute an independent review of the topic by the authors.

What was known before SPYRAL HTN-OFF MED?

Hypertension is highly prevalent and is the most important single risk factor for cardiovascular morbidity and death1. Insufficient blood pressure (BP) control to target values and ...